EGFR and neoplasm: This approach, which proved promising in RAS and BRAF wild-type patients candidate for anti-EGFR re-treatment,23,24 showed encouraging signals of activity also in some case series of patients with BRAFV600E-mutated mCRC reexposed to TT after excluding potential drivers of resistance in their circulating tumor DNA,25,26 and may be an appealing approach for future studies.